{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T15:33:49Z","timestamp":1648913629323},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00120-014-3536-y","type":"journal-article","created":{"date-parts":[[2014,7,14]],"date-time":"2014-07-14T10:20:13Z","timestamp":1405333213000},"page":"1046-1051","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biopsie der Prostata"],"prefix":"10.1007","volume":"53","author":[{"given":"S.","family":"Machtens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Roosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Tru\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,3]]},"reference":[{"key":"3536_CR1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0022-5347(01)61785-3","volume":"161","author":"Carvalhal","year":"1999","unstructured":"Carvalhal GF, Smith DS, Mager DE et al (1999) Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4\u00a0ng\/ml or less. J Urol 161:835\u2013839","journal-title":"J Urol"},{"key":"3536_CR2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ncpuro1294","volume":"6","author":"Loeb","year":"2009","unstructured":"Loeb S, Catalona WJ (2009) What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? Nat Clin Pract Urol 6:68\u201369","journal-title":"Nat Clin Pract Urol"},{"key":"3536_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/fampra\/16.6.621","volume":"16","author":"Hoogendam","year":"1999","unstructured":"Hoogendam A, Buntinx F, Vet HC de (1999) The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract 16(6):621\u2013626","journal-title":"Fam Pract"},{"key":"3536_CR4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1373\/clinchem.2005.059170","volume":"52","author":"Stephan","year":"2006","unstructured":"Stephan C, Klaas M, Muller C et al (2006) Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 52(1):59\u201364","journal-title":"Clin Chem"},{"key":"3536_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jcla.1860040212","volume":"4","author":"Babaian","year":"1990","unstructured":"Babaian RJ, Fritsche HA, Evans RB (1990) Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 4(2):135\u2013137","journal-title":"J Clin Lab Anal"},{"key":"3536_CR6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0022-5347(17)37394-9","volume":"147","author":"Benson","year":"1992","unstructured":"Benson MC, Whang IS, Olsson CA et al (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147(3Pt2):817\u2013821","journal-title":"J Urol"},{"key":"3536_CR7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1464-410X.1994.tb07640.x","volume":"73","author":"Semjonow","year":"1994","unstructured":"Semjonow A, Hamm M, Rathert P, Hertle L (1994) Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and orgam-confined prostatic cancer. Br J Urol 73(5):538\u2013543","journal-title":"Br J Urol"},{"key":"3536_CR8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1515\/CCLM.2009.285","volume":"47","author":"Stephan","year":"2009","unstructured":"Stephan C, K\u00f6pke T, Semjonow A et al (2009) Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med 47:1325\u20131331","journal-title":"Clin Chem Lab Med"},{"key":"3536_CR9","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level \u2264\u20094.0\u00a0ng per milliliter. N Engl J Med 350:2239\u20132246","journal-title":"N Engl J Med"},{"key":"3536_CR10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0027-9684(15)30578-2","volume":"102","author":"Brooks","year":"2010","unstructured":"Brooks DD, Wolf A, Smith RA et al (2010) Prostate cancer screening 2010: updated recommendation from the American Cancer Society. J Natl Med Assoc 102(5):423\u2013429","journal-title":"J Natl Med Assoc"},{"key":"3536_CR11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10552-006-0087-6","volume":"18","author":"Ilic","year":"2007","unstructured":"Ilic D, O\u2019Connor D, Green S, Wilt T (2007) Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 18:279\u2013285","journal-title":"Cancer Causes Control"},{"key":"3536_CR12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10147-007-0742-2","volume":"13","author":"Kobori","year":"2008","unstructured":"Kobori Y, Kitigawa Y, Mizokami A et al (2008) Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1\u201310.0\u00a0ng\/ml as a criterion. Int J Clin Oncol 13:229\u2013232","journal-title":"Int J Clin Oncol"},{"key":"3536_CR13","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2008.19.9794","volume":"27","author":"O","year":"2009","unstructured":"O\u2019Brien MF, Cronin AM, Fearn PA et al (2009) Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediciton of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 27:3591\u20133597","journal-title":"J Clin Oncol"},{"key":"3536_CR14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2008.18.1685","volume":"27","author":"Vickers","year":"2009","unstructured":"Vickers AJ, Savage C, O\u2019Brien MF et al (2009) Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27:398\u2013403","journal-title":"J Clin Oncol"},{"key":"3536_CR15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2006.09.018","volume":"69","author":"Berger","year":"2007","unstructured":"Berger AP, Deibl M, Strasak A et al (2007) Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology 69(1):134\u2013138","journal-title":"Urology"},{"key":"3536_CR16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.urology.2003.09.028","volume":"63","author":"Raaijmakers","year":"2004","unstructured":"Raaijmakers R, Wildhagen MF, Ito K et al (2004) Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63(2):316\u2013320","journal-title":"Urology"},{"key":"3536_CR17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.6004\/jnccn.2010.0016","volume":"8","author":"Kawachi","year":"2010","unstructured":"Kawachi MH, Bahnson RR, Barry M et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 8(2):240\u2013262","journal-title":"J Natl Compr Canc Netw"},{"key":"3536_CR18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1464-410X.2010.09330.x","volume":"106","author":"Remzi","year":"2010","unstructured":"Remzi M, Haese A, Poppel H van et al (2010) Follow-up of men with an elvated PCA3 score indeed predict the presence of prostate cancer? BJU Int 106:1143\u20131147","journal-title":"BJU Int"},{"key":"3536_CR19","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1464-410X.2010.09286.x","volume":"106","author":"Ploussard","year":"2010","unstructured":"Ploussard G, Haese A, Poppel H van et al (2010) The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 106:1143\u20131147","journal-title":"BJU Int"},{"key":"3536_CR20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0022-5347(05)65853-3","volume":"66","author":"Borboroglu","year":"2001","unstructured":"Borboroglu PG, Sur RL, Roberts JL et al (2001) Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol 66(3):866\u2013870","journal-title":"J Urol"},{"key":"3536_CR21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0090-4295(98)00109-5","volume":"51","author":"Iczkowski","year":"1998","unstructured":"Iczkowski KA, Bassler TJ, Schwob VS et al (1998) Diagnosis of \u201esuspicious for malignancy\u201c in prostate biopsies: predictive value for cancer. Urology 51(5):749\u2013757","journal-title":"Urology"},{"key":"3536_CR22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0022-5347(01)66840-X","volume":"154","author":"Davidson","year":"1995","unstructured":"Davidson D, Bostwick DG, Quian J et al (1995) Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predicitive accuracy in needle biopsies. J Urol 154(4):1295\u20131299","journal-title":"J Urol"},{"key":"3536_CR23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.juro.2009.04.016","volume":"182","author":"Merrimen","year":"2009","unstructured":"Merrimen JL, Jones G, Walker D et al (2009) Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol 182:485\u2013490","journal-title":"J Urol"},{"key":"3536_CR24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1148\/radiol.13120641","volume":"268","author":"Arumainayagam","year":"2013","unstructured":"Arumainayagam N, Ahmed HU, Moore CM et al (2013) Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology 268:761\u2013769","journal-title":"Radiology"},{"key":"3536_CR25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.eururo.2013.03.025","volume":"65","author":"Sonn","year":"2014","unstructured":"Sonn GA, Chang E, Natarajan S et al (2014) Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol 65(4):809\u2013815","journal-title":"Eur Urol"},{"key":"3536_CR26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0022-5347(05)00957-2","volume":"175","author":"Eichler","year":"2006","unstructured":"Eichler K, Hempel S, Wilby J et al (2006) Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 175(5):1605\u20131612","journal-title":"J Urol"},{"key":"3536_CR27","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.eururo.2008.03.033","volume":"54","author":"Bootsma","year":"2008","unstructured":"Bootsma AM, Laguna Pes MP, Geerlings SE et al (2008) Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol 54(6):1270\u20131286","journal-title":"Eur Urol"},{"key":"3536_CR28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1464-410x.2000.00576.x","volume":"85","author":"Aron","year":"2000","unstructured":"Aron M, Rajeev TP, Gupta NP (2000) Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 85:682\u2013685","journal-title":"BJU Int"},{"key":"3536_CR29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jac\/dkq471","volume":"66","author":"Cuevas","year":"2011","unstructured":"Cuevas O, Oteo J, lazaro E et al (2011) Spanish EARS-Net Study Group. Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin\/clavulanic acid. J Antimicrob Chemother 66:664\u2013669","journal-title":"J Antimicrob Chemother"},{"key":"3536_CR30","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","volume":"186","author":"Loeb","year":"2011","unstructured":"Loeb S, Carter HB, Berndt SI et al (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186:1830\u20131834","journal-title":"J Urol"},{"key":"3536_CR31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/jcp.56.5.336","volume":"56","author":"Van","year":"2003","unstructured":"Van der Kwast TH, Lopes C, Santonja C et al (2003) Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 56:336\u2013340","journal-title":"J Clin Pathol"},{"key":"3536_CR32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2012.02.055","volume":"62","author":"Fine","year":"2012","unstructured":"Fine SW, Amin MB, Berney DM et al (2012) A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur Urol 62:20\u201339","journal-title":"Eur Urol"},{"key":"3536_CR33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","volume":"29","author":"Epstein","year":"2005","unstructured":"Epstein JL, Allsbrook WC Jr, Amin MB et al (2005) The 2005 international society of urologic pathology (ISUP)consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228\u20131242","journal-title":"Am J Surg Pathol"},{"key":"3536_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cct.2013.11.009","volume":"37","author":"Simmons","year":"2014","unstructured":"Simmons LAM, Ahmed HU, Moore CM (2014) The PICTURE study \u2013 prostate imaging (multi-parametric MRI and prostate Histoscanning TM) compared to transperineal ultrasound guided biopsy for significant prostate cancer. Contemp Clin Trials 37:69\u201383","journal-title":"Contemp Clin Trials"},{"key":"3536_CR35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-0033-1346367","volume":"185","author":"Rothke","year":"2013","unstructured":"Rothke M, Blondin D, Schlemmer HP, Franiel T (2013) PI-RADS classification: structured reporting for MRI of the prostate. RoFo 185(3):253\u2013261","journal-title":"RoFo"},{"key":"3536_CR36","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1464-410X.2008.08205.x","volume":"103","author":"Lawrentschuk","year":"2009","unstructured":"Lawrentschuk N, Fleshner N (2009) The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 103(6):730\u2013733","journal-title":"BJU Int"},{"key":"3536_CR37","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-09-2195","volume":"16","author":"Sciarra","year":"2010","unstructured":"Sciarra A, Panebianco V, Ciccariello M et al (2010) Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 16(6):1875\u20131883","journal-title":"Clin Cancer Res"},{"key":"3536_CR38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.urolonc.2008.03.005","volume":"26","author":"Onik","year":"2008","unstructured":"Onik G, Barzell W (2008) Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 26(5):506\u20135104","journal-title":"Urol Oncol"},{"key":"3536_CR39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2007.06.1126","volume":"70","author":"Barzell","year":"2007","unstructured":"Barzell WE, Melamed MR (2007) Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate \u2013 a 4-year experience. Urology 70(6 Suppl):27\u201335","journal-title":"Urology"},{"key":"3536_CR40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.eururo.2007.02.041","volume":"52","author":"Merrick","year":"2007","unstructured":"Merrick GS, Gutman S, Andreini H et al (2007) Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 52(3):715\u2013723","journal-title":"Eur Urol"},{"key":"3536_CR41","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.urology.2004.10.067","volume":"65","author":"Pinkstaff","year":"2005","unstructured":"Pinkstaff DM, Igel TC, Petrou SP et al (2005) Systematic transperineal ultrasound-guided template biopsy of the prostate: a three-year experience. Urology 65(4):735\u2013739","journal-title":"Urology"},{"key":"3536_CR42","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","volume":"123","author":"Haffner","year":"2013","unstructured":"Haffner MC, Mosburger T, Esopi DM (2013) Tracking the clonal orign of lethal prostate cancer. J Clin Invest 123(11):4918\u20134922","journal-title":"J Clin Invest"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-014-3536-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-014-3536-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-014-3536-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T15:40:08Z","timestamp":1565624408000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-014-3536-y"}},"subtitle":["Update zu Indikation, Durchf\u00fchrung und zuk\u00fcnftiger Entwicklung"],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["3536"],"URL":"https:\/\/doi.org\/10.1007\/s00120-014-3536-y","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}